RUNX3 and neoplasm: Dahn et al., 2020 reported that low-dose DAC (0.5 mg/kg, i.p., administered in 3/5-day cycles) induced the expression of multiple tumor suppressors including RUNX3, CDH1, and BRCA1 in TNBC xenografts derived from MDA-MB-231, MDA-MB-468, and SUM159 cell lines [47].